{"id":753041,"date":"2023-05-01T09:06:33","date_gmt":"2023-05-01T13:06:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-gimoti-patent-listed-in-fda-orange-book\/"},"modified":"2023-05-01T09:06:33","modified_gmt":"2023-05-01T13:06:33","slug":"new-gimoti-patent-listed-in-fda-orange-book","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-gimoti-patent-listed-in-fda-orange-book\/","title":{"rendered":"New GIMOTI Patent Listed in FDA Orange Book"},"content":{"rendered":"

\nBroad Formulation Patent Expands Protection for Gimoti
\n<\/h2>\n
\n

SOLANA BEACH, Calif., May 01, 2023 (GLOBE NEWSWIRE) — Evoke Pharma, Inc.\u00a0(NASDAQ: EVOK),<\/a>\u00a0a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae<\/sup>\u00a0(metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,628,150 is now listed in the U.S. Food and Drug Administration\u00a0(FDA) publication, \u201cApproved Drug Products with Therapeutic Equivalence Evaluations\u201d, commonly known as the \u201cOrange Book\u201d.<\/p>\n

The patent titled \u201cNasal Formulations of Metoclopramide\u201d covers a collection of nasal solutions of metoclopramide and its characteristics when formulated. This new patent is now listed in the FDA\u2019s Orange Book and carries a patent term to 2029. The listing of the patent in the Orange Book adds additional patent protection for GIMOTI beyond the prior two listed patents.<\/p>\n

Patents listed in the Orange Book cover drugs that the FDA has approved and deemed both safe and effective for the general public’s use.\u00a0Inclusion in the book’s list of patents can make it easier for drug makers to monitor for new generic drugs that could potentially arrive on the U.S. market and infringe on their patents.<\/p>\n

\u201cWe are thrilled to be awarded another significant win on the intellectual property front through the listing of our recently granted GIMOTI patent, which will now be our third entry into the FDA\u2019s Orange Book,\u201d commented David Gonyer, Chief Executive Officer of Evoke Pharma. \u201cThis update adds to the list of confirmations from the USPTO regarding our patent estate and continues to affirm the novelty of GIMOTI. We remain committed to pursuing all measures to ensure the long-term availability of GIMOTI to patients who need this evidently important medication.\u201d<\/p>\n

\n About\u00a0Evoke Pharma, Inc.<\/strong>
\n
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in\u00a0the United States\u00a0to treat gastroparesis.<\/p>\n

Visit\u00a0www.EvokePharma.com<\/a>\u00a0for more information.<\/p>\n

Follow GIMOTI on Facebook<\/a>
Follow\u00a0Evoke Pharma\u00a0on Facebook<\/a>
Follow\u00a0Evoke Pharma\u00a0on LinkedIn<\/a>
Follow Evoke Pharma on Twitter<\/a><\/p>\n

\n About Gimoti\u2122 (metoclopramide) nasal spray<\/strong>
\n
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.<\/p>\n

\n Important Safety Information<\/strong>
\n
WARNING: TARDIVE DYSKINESIA<\/p>\n